KAPOSI SARCOMA TREATMENT MARKET ANALYSIS

Regional Analysis

Kaposi Sarcoma Treatment Market - Regional Analysis

On the basis of region, the Kaposi sarcoma treatment market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds a leading position in the global Kaposi sarcoma treatment market, owing to the presence of various key players in the region and the rising cost of Kaposi sarcoma treatment drugs. The North America market for also benefits from the high rate of diagnosis of the sarcoma condition.

Moreover, North America is witnessing a shortage in supply of drugs required for its treatment, leading to a wide demand-supply gap and subsequently significant slower scope for growth. For instance, in January 2016, Eisai Co., Ltd. issued the shortage notice by stating that, due to the manufacturing issue, there was a supply shortage of Panretin gel tubes (US FDA approved) in U.S. Moreover, in order to alleviate the shortage of Panretin gel in the U.S., FDA approved the sales of Panretin gel tubes for use in the European market.

Africa is expected to gain a significant traction, owing to the increasing prevalence of HIV infection in this region. For instance, according to the data published in Journal of Acquired Immune Deficiency Syndromes, in December 2014, Kaposi sarcoma is most common cancer among HIV-infected persons in Southern Africa. Moreover, 30%-50% HIV infected persons in these region are co-infected with human herpesvirus 8 (HHV-8), which is causative agent of Kaposi sarcoma.

By Geography:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa